13 October 2020
In this video, Duncan Porter, Senior Director and leader of the Clinical Microbiology segment at Thermo Fisher Scientific, describes the power of rapid antimicrobial susceptibility testing (AST) to not only provide timely, actionable results in a single shift , but form a fundamental part of antibiotic stewardship. Porter illustrates how the time to targeted therapy is key to recovery for critically ill patients, and by adopting rapid AST, clinicians can access information around the correct therapy sooner.
This video is the first installment in our four-part series exploring the diagnostic labs of the future. Follow the links below for the complete series: